New drug VTX3232 tested for safety in early Parkinson's patients
NCT ID NCT06556173
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether the drug VTX3232 is safe for people with early-stage Parkinson's disease. Eleven participants took the drug for 28 days and were monitored for side effects. The goal was to check safety and how the drug moves through the body, not to cure the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PARKINSON DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Local Site #840001
New Haven, Connecticut, 06510, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Virtual therapy shows promise for Parkinson's balance
- Brain scans reveal clues to mysterious MSA disorder
- New french questionnaire to measure physical activity in disabled individuals
- Parkinson's patients try antioxidant supplements to boost brain health
- Simple blood test may predict Parkinson's progression
- New turkish questionnaire aims to better measure Parkinson's movement side effects